Mar 9, 2026
positiveFDA's Vinay Prasad to Exit Biologics Post in April, Sending Biotech Stocks Sharply Higher
The announced departure of Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, triggered a significant rally in biotech equities Monday, with uniQure surging more than 31% in premarket trading. Investors interpreted the news as a signal that the agency may adopt a more predictable and industry-friendly regulatory posture for vaccines, gene therapies, and rare disease treatments.







